The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years

Despite the positive results achieved by Imatinib mesylate (Imatinib) in the treatment of chronic myeloid leukemia (CML), over the past several years, Imatinib does not eradicate the leukemic clone. The long-term duration of response to the drug is not known. Long-term follow-up of CML patients trea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cells, molecules, & diseases molecules, & diseases, 2006-09, Vol.37 (2), p.111-115
Hauptverfasser:	Piazza, Rocco G., Magistroni, Vera, Franceschino, Anna, Andreoni, Federica, Tornaghi, Lucia, Colnaghi, Federica, Corneo, Gianmarco, Pogliani, Enrico M., Gambacorti-Passerini, Carlo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged BCR-ABL Benzamides Chronic myeloid leukemia Cohort Studies Cytogenetic Analysis - methods Data Interpretation, Statistical Drug Administration Schedule Drug resistance Follow-Up Studies Humans Imatinib Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Middle Aged Piperazines - therapeutic use Predictive Value of Tests Pyrimidines - therapeutic use Recurrence Remission Remission Induction Reverse Transcriptase Polymerase Chain Reaction Survival Rate Time Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!